These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18415880)

  • 21. Schizophrenia and weight management: a systematic review of interventions to control weight.
    Faulkner G; Soundy AA; Lloyd K
    Acta Psychiatr Scand; 2003 Nov; 108(5):324-32. PubMed ID: 14531752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity.
    Erickson ZD; Kwan CL; Gelberg HA; Arnold IY; Chamberlin V; Rosen JA; Shah C; Nguyen CT; Hellemann G; Aragaki DR; Kunkel CF; Lewis MM; Sachinvala N; Sonza PA; Pierre JM; Ames D
    J Gen Intern Med; 2017 Apr; 32(Suppl 1):32-39. PubMed ID: 28271424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric medication-induced obesity: treatment options.
    Schwartz TL; Nihalani N; Virk S; Jindal S; Chilton M
    Obes Rev; 2004 Nov; 5(4):233-8. PubMed ID: 15458397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of metformin to limit weight-gain with atypical antipsychotics.
    Lee YJ; Jeong JH
    J Clin Pharm Ther; 2011 Oct; 36(5):537-45. PubMed ID: 21418264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum.
    Holt RIG
    Psychother Psychosom; 2019; 88(6):327-332. PubMed ID: 31587002
    [No Abstract]   [Full Text] [Related]  

  • 26. [Non-pharmacological interventions for weight gain in patients with schizophrenia taking antipsychotics].
    Attux C; Martini LC; Reis AF; Bressan RA
    Arq Bras Endocrinol Metabol; 2009 Jun; 53(4):391-8. PubMed ID: 19649375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk.
    Smith C; Myles H; Galletly C
    Australas Psychiatry; 2017 Aug; 25(4):387-390. PubMed ID: 28747113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.
    Faulkner G; Cohn TA
    Can J Psychiatry; 2006 Jul; 51(8):502-11. PubMed ID: 16933587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of antipsychotic-associated weight gain.
    O'Keefe CD; Noordsy DL; Liss TB; Weiss H
    J Clin Psychiatry; 2003 Aug; 64(8):907-12. PubMed ID: 12927005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Pediatric Obesity: An Umbrella Systematic Review.
    Rajjo T; Mohammed K; Alsawas M; Ahmed AT; Farah W; Asi N; Almasri J; Prokop LJ; Murad MH
    J Clin Endocrinol Metab; 2017 Mar; 102(3):763-775. PubMed ID: 28359101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity in patients with severe mental illness: overview and management.
    McElroy SL
    J Clin Psychiatry; 2009; 70 Suppl 3():12-21. PubMed ID: 19570497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral treatment of obesity in patients taking antipsychotic medications.
    Kalarchian MA; Marcus MD; Levine MD; Haas GL; Greeno CG; Weissfeld LA; Qin L
    J Clin Psychiatry; 2005 Aug; 66(8):1058-63. PubMed ID: 16086623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
    Khan AY; Macaluso M; McHale RJ; Dahmen MM; Girrens K; Ali F
    J Psychiatr Pract; 2010 Sep; 16(5):289-96. PubMed ID: 20859106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?
    Correll CU
    J Clin Psychiatry; 2005 Oct; 66(10):1331-2. PubMed ID: 16259549
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.